DTHF WELCOMES EARLY DATA FROM ENSEMBLE TRIAL, SHOWING SAFETY & EFFICACY FOR SINGLE -SHOT JANSSEN COVID-19 VACCINE CANDIDATE

Johnson & Johnson today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating its investigational single-dose COVID-19 vaccine met all primary and key secondary endpoints. The topline safety and efficacy data are based on 44,325 44 participants accruing 468 symptomatic cases of COVID-19. The Desmond Tutu Health Foundation is a…